Texas Business Times
SEE OTHER BRANDS

Hottest business and economy news from Texas

Texas Business Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Texas Business Times.

Press releases published on May 5, 2025

Tyson Foods Reports Second Quarter 2025 Results

Tyson Foods Reports Second Quarter 2025 Results

SPRINGDALE, Ark., May 05, 2025 (GLOBE NEWSWIRE) -- Tyson Foods, Inc. (NYSE: TSN), one of the world’s largest food companies and a recognized leader in protein with leading brands including Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Wright, Aidells, ibp …

SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025

SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025

Novel RBM39 molecular glue achieves complete tumor regression in mechanism-based Ewing sarcoma models; IND filing expected mid-2025 Dual PROTAC strategy overcomes hook effect and enhances KRAS G12D degradation in collaboration with University of …

Creative Realities, Inc. Announces First Quarter 2025 Earnings Release Date and Conference Call Information

Creative Realities, Inc. Announces First Quarter 2025 Earnings Release Date and Conference Call Information

LOUISVILLE, Ky., May 05, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. ("Creative Realities," "CRI," or the "Company") (NASDAQ: CREX), a leading provider of digital signage and media solutions, announced today that it will release its financial results …

SunHydrogen Contracts The Process Group for Front-End Engineering Design of 25m2 Renewable Hydrogen Pilot Plant

SunHydrogen Contracts The Process Group for Front-End Engineering Design of 25m2 Renewable Hydrogen Pilot Plant

Coralville, IA, May 05, 2025 (GLOBE NEWSWIRE) -- SunHydrogen, Inc. (OTC: HYSR), the developer of innovative technologies for producing renewable hydrogen using sunlight and water, today announced that it has contracted The Process Group, LLC (TPG Engineers …

SEALSQ’s VaultIC 408 Meets FIPS 140-3 Requirements, Advancing NIST Certification and Strengthening Leadership in Secure IoT and Smart Grid Solutions

SEALSQ’s VaultIC 408 Meets FIPS 140-3 Requirements, Advancing NIST Certification and Strengthening Leadership in Secure IoT and Smart Grid Solutions

Geneva, Switzerland, May 05, 2025 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced a …

USA Rare Earth Announces Closing of $75 Million PIPE Financing

USA Rare Earth Announces Closing of $75 Million PIPE Financing

STILLWATER, Okla., May 05, 2025 (GLOBE NEWSWIRE) -- USA Rare Earth, Inc. (Nasdaq: USAR) (USAR or the Company), today announced the closing of its previously announced private investment in public equity (PIPE) financing. The PIPE is with a single …

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

—Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)— —Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million— —Company now expects to be profitable for full year 2025, a year ahead of schedule— —Company pays down …

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025 SELARSDI is approved for all indications …

As Federal Collections Activity Resumes, More Than One in Five Federal Student Loan Borrowers With a Payment Due are Seriously Delinquent

As Federal Collections Activity Resumes, More Than One in Five Federal Student Loan Borrowers With a Payment Due are Seriously Delinquent

CHICAGO, May 05, 2025 (GLOBE NEWSWIRE) -- As the U.S. Department of Education begins resuming collections activities among defaulted borrowers, new research reveals that the number of consumers at risk for default has soared past pre-pandemic levels. These …

Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma

Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- IGI, Inc., a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics™ in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track …

IRADIMED CORPORATION Announces First Quarter 2025 Financial Results

IRADIMED CORPORATION Announces First Quarter 2025 Financial Results

Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in …

Aquestive Therapeutics to Participate in Citizens Life Sciences Conference

Aquestive Therapeutics to Participate in Citizens Life Sciences Conference

WARREN, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete remissions, and MRD negativity across …

Colliers adds leading telecommunications engineering firm

Colliers adds leading telecommunications engineering firm

TORONTO and CHICAGO, May 05, 2025 (GLOBE NEWSWIRE) -- Leading diversified professional services and investment management company, Colliers (NASDAQ, TSX: CIGI), announced today that its Colliers Engineering …

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced …

EnviroGold Global Announces Appointment of Paul McRae as Non-Executive Chair

EnviroGold Global Announces Appointment of Paul McRae as Non-Executive Chair

TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK) (“EnviroGold,” or the “Company”), a clean technology company unlocking significant value from mine waste and tailings while promoting environmental …

Apollo Silver Appoints Ross McElroy as President and CEO

Apollo Silver Appoints Ross McElroy as President and CEO

VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Apollo Silver Corp. (“Apollo” or the “Company”) (TSX.V:APGO, OTCQB:APGOF, Frankfurt:6ZF0) is pleased to announce the appointment of Mr. Ross McElroy as President and CEO, effective immediately, …

PLBY Group to Report First Quarter 2025 Financial Results on May 15, 2025

PLBY Group to Report First Quarter 2025 Financial Results on May 15, 2025

LOS ANGELES, May 05, 2025 (GLOBE NEWSWIRE) -- PLBY Group, Inc. (NASDAQ: PLBY) (“PLBY Group” or the “Company”), a leading pleasure and leisure lifestyle company and owner of Playboy, one of the most recognizable and iconic brands in the world, will report …

GXO and Blue Yonder Announce New Strategic Global Agreement

GXO and Blue Yonder Announce New Strategic Global Agreement

New agreement creates strategic growth opportunities for both companies while delivering industry-leading supply chain solutions for customers GREENWICH, Conn. and DALLAS, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- GXO Logistics, Inc. (NYSE: GXO), the world’s …

Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September

Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September

MaGic trial exceeded enrollment target of 60 patients Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26 Building a neuromuscular franchise with DNTH103 in gMG, CIDP and MMN with a potential best-in-class, …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service